Whilst the potential of targeting the epigenetic machinery for cancer therapy is increasingly recognized (35), and over-expression of G9a has been reported in many cancers (36), targeted inhibition of G9a is relatively understudied. The gene discussed is EHMT2; the disease is cancer.